2021
Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere disease
2017
Interleukin-6 receptor α signaling on CD4+ T cells drives RBC alloantibody generation and T follicular helper cell differentiation in a murine model of RBC alloimmunization.
Arneja A, Salazar J, Jiang W, Hendrickson J, Zimring J, Luckey C. Interleukin-6 receptor α signaling on CD4+ T cells drives RBC alloantibody generation and T follicular helper cell differentiation in a murine model of RBC alloimmunization. The Journal Of Immunology 2017, 198: 201.27-201.27. DOI: 10.4049/jimmunol.198.supp.201.27.Peer-Reviewed Original ResearchRBC alloimmunizationRed blood cellsIL-6RαT cellsAntigen-negative red blood cellsFollicular helper cell differentiationInterleukin-6 receptor αFollicular helper cellsHemolytic transfusion reactionsViable therapeutic optionLife-saving therapySignificant clinical problemSignificant clinical consequencesInterleukin-6 receptorHelper cell differentiationSpecific CD4Multiple alloantibodiesOccasional mortalitySignificant morbidityTherapeutic optionsAvailable biologicsFunctional outcomeHelper cellsTransfusion reactionsClinical consequences